"I am incredibly proud of the progress our team has made this year with two positive data read-outs in our indications and subsequent successful financings," said Jennifer Good. "At our R&D Day in September, we announced the final positive results from our Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in IPF that demonstrated a strong magnitude of effect on cough and statistically significant data for the primary efficacy endpoint and other key secondary endpoints. We have approximately $126M in cash, cash equivalents, and investments at the end of the quarter, which we plan to use to fund further development in our targeted cough indications."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TRVI:
